Isaac Barchas Biography and Net Worth

Director of Immunome

Isaac Barchas is CEO and co-founder of Research Bridge Partners, a biotechnology accelerator. Barchas built RBP’s team and strategy and co-manages new venture creation and investment activity. At Research Bridge Partners, Barchas has served as founding board member of Tetricus, Eradivir, and MorphImmune and as lead turnaround board member of Novosteo (NASDAQ: QNCX). Barchas is also a managing director of RBP-Catalyst Fund I and Arsenal Bridge Ventures II.

Prior to founding Research Bridge Partners, Barchas led the Austin Technology Incubator. Under Barchas’ leadership, ATI companies raised ~$1B in investor capital. Barchas came to ATI from McKinsey & Co., where he served in the Chicago, Sydney, Auckland, and Dallas offices. Barchas served on the leadership teams of McKinsey’s North American Payor/Provider and global Organization practices. Barchas received his AB from Stanford University and his Master’s and JD degrees from The University of Chicago.

What is Isaac Barchas' net worth?: The estimated net worth of Isaac Barchas is at least $50.01 million as of December 22nd, 2025. Barchas owns 2,031,181 shares of Immunome stock worth more than $50,007,676 as of January 30th. This net worth estimate does not reflect any other investments that Barchas may own. Learn More about Isaac Barchas' net worth.
How do I contact Isaac Barchas?: The corporate mailing address for Barchas and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at [email protected]. Learn More on Isaac Barchas' contact information.
Has Isaac Barchas been buying or selling shares of Immunome?: Isaac Barchas has not been actively trading shares of Immunome in the last ninety days. Most recently, Isaac Barchas sold 383,200 shares of the business's stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $21.74, for a transaction totalling $8,330,768.00. Following the completion of the sale, the director now directly owns 2,031,181 shares of the company's stock, valued at $44,157,874.94. Learn More on Isaac Barchas' trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Isaac Barchas (Director), Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), and Bruce Turner (Insider). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 9 times. They purchased a total of 379,918 shares worth more than $3,823,853.29. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 383,200 shares worth more than $8,330,768.00. The most recent insider tranaction occured on December, 30th when CEO Clay B Siegall bought 4,729 shares worth more than $100,018.35. Insiders at Immunome own 7.7% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 12/30/2025.

Isaac Barchas Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/22/2025	Sell	383,200	$21.74	$8,330,768.00	2,031,181

Isaac Barchas Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $24.62

$23.67

$25.26

50 Day Range

MA: $21.30

$17.09

$25.87

2 Week Range

Now: $24.62

$5.15

$26.63

Volume

1,358,831 shs

Average Volume

2,053,538 shs

Market Capitalization

$2.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22